Literature DB >> 32705384

Risk adapted diagnostics and hospitalization following mild traumatic brain injury.

Lukas Leitner1, Jasmin Helena El-Shabrawi2, Gerhard Bratschitsch2, Nicolas Eibinger2, Sebastian Klim2, Andreas Leithner2, Paul Puchwein2.   

Abstract

INTRODUCTION: Traumatic brain injury (TBI) remains a leading cause of hospital admission and mortality, intracranial hemorrhage (ICH) presents a severe complication. Low complication tolerance in developed countries and risk uncertainty, often cause excessive observation, diagnostics and hospitalization, considered unnecessary and expensive. Risk factors predicting ICH, progression and death in patients hospitalized with mild TBI have not been identified yet.
METHODS: Mild TBI cases indicated for cranial computer tomography (CT) and hospitalization, according to international guidelines, at our Level I Trauma Center between 2008 and 2018 were retrospectively included. Multivariate logistic regression was performed for ICH, progression and mortality predictors.
RESULTS: 1788 mild TBI adults (female: 44.3%; age at trauma: 58.0 ± 22.7), were included. Skull fracture was diagnosed in 13.8%, ICH in 46.9%, ICH progression in 10.6%. In patients < 35 years with mild TBI, chronic alcohol consumption (p = 0.004) and skull fracture (p < 0.001) were significant ICH risk factors, whilst in patients between 35 and 65 years, chronic alcohol consumption (p < 0.001) and skull fracture (p < 0.001) revealed as significant ICH predictors. In patients with mild TBI > 65 years, age (p = 0.009), anticoagulation (p = 0.007) and neurocranial fracture (p < 0.001) were significant, independent risk factors for ICH, whilst increased age (p = 0.01) was a risk factor for mortality following ICH in mild TBI. Late-onset ICH only occurred in mild TBI cases with at least two of these risk factors: age > 65, anticoagulation, neurocranial fracture. Overall hospitalization could have been reduced by 15.8% via newly identified low-risk cases.
CONCLUSIONS: Age, skull fracture and chronic alcohol abuse require vigilant observation. Repeated CT in initially ICH negative cases should only be considered in newly identified high-risk patients. Non-ICH cases aged < 65 years do not gain safety from observation or hospitalization. Recommendations from our data might, without impact on patient safety, reduce costs by unnecessary hospitalization and diagnostics.

Entities:  

Keywords:  Hospitalization; Intracranial bleeding; Prognosis; Risk estimation; TBI

Mesh:

Year:  2020        PMID: 32705384      PMCID: PMC7966191          DOI: 10.1007/s00402-020-03545-w

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  27 in total

1.  Canadian CT head rule study for patients with minor head injury: methodology for phase II (validation and economic analysis).

Authors:  I G Stiell; H Lesiuk; G A Wells; D Coyle; R D McKnight; R Brison; C Clement; M A Eisenhauer; G H Greenberg; I Macphail; M Reardon; J Worthington; R Verbeek; B Rowe; D Cass; J Dreyer; B Holroyd; L Morrison; M Schull; A Laupacis
Journal:  Ann Emerg Med       Date:  2001-09       Impact factor: 5.721

2.  The novel oral anticoagulants (NOACs) have worse outcomes compared with warfarin in patients with intracranial hemorrhage after TBI.

Authors:  Muhammad Zeeshan; Faisal Jehan; Terence O'Keeffe; Muhammad Khan; El Rasheid Zakaria; Mohammad Hamidi; Lynn Gries; Narong Kulvatunyou; Bellal Joseph
Journal:  J Trauma Acute Care Surg       Date:  2018-11       Impact factor: 3.313

Review 3.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.

Authors:  Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

4.  Rivaroxaban and intracranial haemorrhage after mild traumatic brain injury: A dangerous combination?

Authors:  Christopher Beynon; Anna Potzy; Oliver W Sakowitz; Andreas W Unterberg
Journal:  Clin Neurol Neurosurg       Date:  2015-05-30       Impact factor: 1.876

5.  Patterns of intracranial hemorrhage in petrous temporal bone fracture.

Authors:  Zamzil Amin Asha'ari; Raja Ahmad; Jamalludin Rahman; Rosnida Azura Yusof; Norie Kamarudin
Journal:  Auris Nasus Larynx       Date:  2011-05-17       Impact factor: 1.863

Review 6.  Coagulopathy and haemorrhagic progression in traumatic brain injury: advances in mechanisms, diagnosis, and management.

Authors:  Marc Maegele; Herbert Schöchl; Tomas Menovsky; Hugues Maréchal; Niklas Marklund; Andras Buki; Simon Stanworth
Journal:  Lancet Neurol       Date:  2017-07-11       Impact factor: 44.182

7.  Comparison of early and late depression after TBI; (the SHEFBIT study).

Authors:  Rajiv Singh; Suzanne Mason; Fiona Lecky; Jeremy Dawson
Journal:  Brain Inj       Date:  2019-01-19       Impact factor: 2.311

8.  Nonsurgical acute traumatic subdural hematoma: what is the risk?

Authors:  Paul Bajsarowicz; Ipshita Prakash; Julie Lamoureux; Rajeet Singh Saluja; Mitra Feyz; Mohammad Maleki; Judith Marcoux
Journal:  J Neurosurg       Date:  2015-05-08       Impact factor: 5.115

Review 9.  Alcohol Use Disorder and Traumatic Brain Injury.

Authors:  Zachary M Weil; John D Corrigan; Kate Karelina
Journal:  Alcohol Res       Date:  2018

10.  Clinical predictive score of intracranial hemorrhage in mild traumatic brain injury.

Authors:  Chaiyaporn Yuksen; Yuwares Sittichanbuncha; Jayanton Patumanond; Sombat Muengtaweepongsa; Kittisak Sawanyawisuth
Journal:  Ther Clin Risk Manag       Date:  2018-02-01       Impact factor: 2.423

View more
  1 in total

1.  Nomogram for predicting traumatic subdural effusion after mild traumatic brain injury.

Authors:  Lichao Wei; Bowen Chang; Zhi Geng; Ming Chen; Yongsheng Cao; Liang Yao; Chao Ma
Journal:  Front Neurol       Date:  2022-09-01       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.